

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

IN RE APPLICATION OF: Savion et al.

SERIAL NO: 09/341,048

GAU: 1614

MAY 08 2001

FILED: August 9, 1999

EXAMINER: Z. Fay

TECH CENTER 1600/2900

Pharmaceutical Compositions for the Treatment of the Eye

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

HONORABLE COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a copy of applicant's pending application(s) or issued patent(s) which may be related to the present application. These documents are listed on form PTO-1449, also attached.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of the subject patent application.
- ☐ This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

PETITION

- Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(i)(1).

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

05/07/2001 HNDOR1 00000017 09341048

01 FC:126

180.00 OP

THE FARRAGUT BUILDING
SUITE 1000
900 17TH STREET, NW
WASHINGTON, DC 20006
TEL (202) 530-7400
FAX (202) 463-6915

Respectfully Submitted,

BLANK ROME COMISKY & MCCAULEY LLP

Herbert Cohen
Attorney of Record
Registration No. 25,109

Date: May 4, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

IN RE APPLICATION OF: Savion et al.

SERIAL NO: 09/341,048

FILED: August 9, 1999

Pharmaceutical Compositions for the Treatment of the Eye

GAU: 1614

EXAMINER: MAY 08 2001

RECEIVED

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

HONORABLE COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a copy of applicant's pending application(s) or issued patent(s) which may be related to the present application. These documents are listed on form PTO-1449, also attached.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☐ This Information Disclosure Statement is being filed within three months of the filing date of the subject patent application.
- ☐ This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

PETITION

- ☒ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(i)(1).

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

BLANK ROME COMISKY & MCCAULEY LLP

Herbert Cohen
Attorney of Record
Registration No. 25,109

THE FARRAGUT BUILDING
SUITE 1000
900 17TH STREET, NW
WASHINGTON, DC 20006
TEL (202) 530-7400
FAX (202) 463-6915

Date: May 4, 2001